We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




15-Minute Multiplex Molecular Tests to Detect STI at Point-of-Care

By LabMedica International staff writers
Posted on 01 Feb 2024

Annually, between 35 and 50 million tests for chlamydia and gonorrhea are conducted in the United States, largely driven by guidelines recommending annual STI screenings for many sexually active individuals and even more frequent tests for specific high-risk groups. More...

Despite these recommendations, about half of the women eligible for screening do not undergo proper testing each year, leading to significant undertesting. Additionally, the time delay in lab-based testing can result in patients remaining untreated and potentially spreading infections, or in preemptive treatments based on best guesses that may be inappropriate, causing unnecessary costs, side effects, and potential development of antimicrobial resistance. Now, a new rapid, portable molecular STI test promises to deliver immediate results to patients and providers, enabling prompt treatment and potentially improving health outcomes, especially for patients who might otherwise postpone or forego testing.

Detect (Guilford, CT, USA) is gearing up to begin clinical validations for its 15-minute multiplex molecular STI test, based on a technology initially developed for tackling the COVID-19 pandemic. This testing relies on loop-mediated isothermal amplification (LAMP) and a simple instrument, aiming for affordability, speed, and ease of use. The instrument performs parallel reactions for quick multiplexing, as opposed to single-tube reactions. While LAMP is a widely used technology, Detect has enhanced it considerably in recent years. Challenges in LAMP for diagnostics developers, such as primer design and reaction speed, have been addressed by Detect's use of AI-based primer design tools to develop highly sensitive and specific tests. The tests also incorporate proprietary biologics like enzymes, which are self-designed and manufactured by Detect, leading to faster and more accurate results.

Detect has leveraged the same technology used for its COVID-19 test to expand its applications and upgrade the system, making it faster, more user-friendly, and more sensitive. This evolution has resulted in an advanced point-of-care system and new multiplex molecular tests. The company is now advancing its initial isothermal multiplex panel for STIs. Dealing with STI testing presented a unique challenge in sample preparation, as vaginal matrix samples, unlike saliva or nasal secretions, require additional preparation steps to make pathogens accessible. Detect has addressed this major technical hurdle by creating a cost-effective, miniaturized sample preparation component for its system. The test cartridge itself is composed of simple plastic fluidic components, shifting complex electronics or motors from the cartridge to the hub, thus reducing the cost of the cartridge.

Detect's primary market includes point-of-care testing locations like doctors' offices, urgent care clinics, nursing homes, and pharmacies, which are typically more concerned with the ongoing cost of consumables rather than the initial cost of the testing device. The company anticipates its platform to be substantially more affordable than other point-of-care systems currently on the market. Detect is focusing on validating its rapid molecular STI assay in the coming months to prepare for submission to the US Food and Drug Administration. In the future, Detect plans to enhance its STI panel to identify specific SNPs in gonorrhea bacteria that render them resistant to ciprofloxacin, a low-cost antibiotic.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: The new tool is designed for accurate detection of structural variations in clinical samples (Photo courtesy of Karen Arnott/EMBL-EBI and Isabel Romero Calvo/EMBL)

ML Algorithm Accurately Identifies Cancer-Specific Structural in Long-Read DNA Sequencing Data

Long-read sequencing technologies are designed to analyze long, continuous stretches of DNA, offering significant potential to enhance researchers' abilities to detect complex genetic changes in cancer genomes.... Read more

Technology

view channel
Image: Concept of biosensor integrated into hygiene pads enabling direct semi-quantitative analysis of biomarkers in unprocessed menstruation blood (Photo courtesy of Dosnon, L et al. DOI: 10.1002/advs.202505170)

First Ever Technology Recognizes Disease Biomarkers Directly in Menstrual Blood in Sanitary Towels

Over 1.8 billion people menstruate worldwide, yet menstrual blood has been largely overlooked in medical practice. This blood contains hundreds of proteins, many of which correlate with their concentration... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.